D-amphetamine-induced behavioral sensitization: Implication of a glutamatergic medial prefrontal cortex-ventral tegmental area innervation

被引:138
|
作者
Cador, M [1 ]
Bjijou, Y [1 ]
Cailhol, S [1 ]
Stinus, L [1 ]
机构
[1] Univ Bordeaux 2, Lab Neuropsychobiol Desadaptat, CNRS UMR 5541, F-33076 Bordeaux, France
关键词
ventral tegmental area; medial prefrontal cortex; amygdala; behavioral sensitization; glutamate;
D O I
10.1016/S0306-4522(99)00361-9
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Behavioral sensitization to amphetamine is expressed as a progressive enhancement of the behavioral activating effects of the drug when repeated injections are performed as well as a long-lasting hypersensitivity to later environmental or pharmacological challenges. The mesoaccumbens dopamine system has been proposed to be the major candidate so far responsible for the induction and expression of this process, which are dependent on the action of amphetamine in the ventral tegmental area and nucleus accumbens, respectively. The development of this process has been proposed to be the result of an interaction between somatodendritically released dopamine and dopaminergic D-1 receptors localized on different inputs to the ventral tegmental area, including glutamate afferents arising in part from mesocorticolimbic areas such as the medial prefrontal cortex and the amygdala, Three groups of experiments were designed to test the role of each of these components in the behavioral sensitization to amphetamine. First, the intervention of the glutamatergic transmission of the ventral tegmental area in the induction of sensitization to amphetamine was tested. The effects of an iv-methyl-D-aspartate antagonist, 3-(R-2-carboxypiperazin-4-yl) -propyl-1-phosphonic acid, on the behavioral sensitization induced by amphetamine administered repeatedly in the ventral tegmental area was tested. It was found that the blockade of N-methyl-D-aspartate receptors with 3-(R-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid coadministered with amphetamine in the ventral tegmental area dose-dependently prevented the induction of sensitization. In a second step, the role of the structures which send glutamatergic inputs to the ventral tegmental area in the process of behavioral sensitization was tested. We evaluated the effects of ibotenic acid lesion of the medial prefrontal cortex and the amygdala on behavioral sensitization induced by peripheral or intra-ventral tegmental area administration of amphetamine. We found that ibotenic acid lesion of the medial prefrontal cortex blocked the behavioral sensitization induced by both intra-ventral tegmental area and peripheral treatment with amphetamine. In contrast, ibotenic acid lesion of the amygdala produced no effect on behavioral sensitization induced peripherally or centrally. These experiments confirmed (i) that the ventral tegmental area, where dopaminergic cell bodies are located, is a critical site for the induction of behavioral sensitization, (ii) that this process implicates the glutamatergic transmission in the ventral tegmental area, and (iii) that the medial prefrontal cortex is crucially implicated merely because of its direct glutamatergic inputs on to ventral tegmental area neurons. Together, these results reinforce the view that the behavioral sensitization to amphetamine implicates not only the mesoaccumbens dopaminergic neurons, but also other structures of the mesocorticolimbic system, such as the medial prefrontal cortex and more specifically its glutamatergic component. (C) 1999 IBRO. Published by Elsevier Science Ltd.
引用
收藏
页码:705 / 721
页数:17
相关论文
共 50 条
  • [1] D-amphetamine-induced behavioral sensitization: Effect of lesioning dopaminergic terminals in the medial prefrontal cortex, the amygdala and the entorhinal cortex
    Bjijou, Y
    De Deurwaerdere, P
    Spampinato, U
    Stinus, L
    Cador, M
    NEUROSCIENCE, 2002, 109 (03) : 499 - 516
  • [2] D-amphetamine-induced behavioral sensitization:: Implication of neurotensin receptors
    Bérod, A
    Panayi, F
    Renaud, B
    Scarna, H
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 : 96 - 96
  • [3] Sensitized activation of Fos and brain-derived neurotrophic factor in the medial prefrontal cortex and ventral tegmental area accompanies behavioral sensitization to amphetamine
    Fanous, Sanya
    Lacagnina, Michael J.
    Nikulina, Ella M.
    Hammer, Ronald P., Jr.
    NEUROPHARMACOLOGY, 2011, 61 (04) : 558 - 564
  • [4] Clozapine blocks D-amphetamine-induced excitation of dopamine neurons in the ventral tegmental area
    Shi, Wei-Xing
    Zhang, Xiang-Yang
    Pun, Chen-Lun
    Bunney, Benjamin S.
    NEUROPSYCHOPHARMACOLOGY, 2007, 32 (09) : 1922 - 1928
  • [5] Clozapine Blocks D-Amphetamine-Induced Excitation of Dopamine Neurons in the Ventral Tegmental Area
    Wei-Xing Shi
    Xiang-Yang Zhang
    Chen-Lun Pun
    Benjamin S Bunney
    Neuropsychopharmacology, 2007, 32 : 1922 - 1928
  • [6] Endogenous Neurotensin in the Ventral Tegmental Area Contributes to Amphetamine Behavioral Sensitization
    Fany Panayi
    Joyce Colussi-Mas
    Laura Lambás-Señas
    Bernard Renaud
    Hélène Scarna
    Anne Bérod
    Neuropsychopharmacology, 2005, 30 : 871 - 879
  • [7] Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization
    Panayi, F
    Colussi-Mas, J
    Lambás-Señas, L
    Renaud, B
    Scarna, H
    Bérod, A
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 (05) : 871 - 879
  • [8] ADAPTATIONS IN MEDIAL PREFRONTAL CORTEX FUNCTION ASSOCIATED WITH AMPHETAMINE-INDUCED BEHAVIORAL SENSITIZATION
    Gulley, J. M.
    Stanis, J. J.
    NEUROSCIENCE, 2010, 166 (02) : 615 - 624
  • [9] Valence-Specific Gating of Behavioral Flexibility by Medial Prefrontal Cortex Projections to the Ventral Tegmental Area
    Lefner, Merridee
    Moghaddam, Bita
    NEUROPSYCHOPHARMACOLOGY, 2023, 48 : 123 - 123
  • [10] Evidence for selective involvement of dopamine D-1 receptors of the ventral tegmental area in the behavioral sensitization induced by intra-ventral tegmental area injections of D-amphetamine
    Bjijou, Y
    Stinus, L
    LeMoal, M
    Cador, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1996, 277 (02): : 1177 - 1187